Antivirals Market Poised for 7.6% Growth, Set to Hit $2.78 Billion by 2029

"How Is the Antivirals Market Projected to Grow, and What Is Its Market Size?
The antivirals market has seen robust growth in recent years, with its size set to rise from $106.13 billion in 2024 to $114.7 billion in 2025, marking a compound annual growth rate (CAGR) of 8.1%. Factors such as the widespread prevalence of viral diseases, communal health worries, the expiration of patents, and governmental efforts have contributed to growth during the past period.

Over the coming years, the antivirals market is anticipated to experience robust growth, with its size set to reach $153.67 billion in 2029, registering a compound annual growth rate (CAGR) of 7.6%. The growth projection during this period is largely due to the rise in viral threats and global health initiatives. The key trends expected during this forecast period include technological progression, the rise of telemedicine and digital health, and the growth of personalized medicine.

What Are the Key Drivers Behind the Growth of the Antivirals Market?
The upward trend in flu cases is expected to boost the antiviral market in the future. Influenza, commonly known as the flu, is a highly infectious viral infection of the respiratory system caused by influenza viruses which affect the nose, throat and lungs. Antivirals are deployed in fighting influenza as they are designed to stop the replication and spread of the flu virus in the body. For example, data from the US-based health agency, the Centers for Disease Control and Prevention in October 2022 showed that during the 2021-2022 season, there were 9 million reported cases of flu, 4 million flu-related doctor visits, 100,000 flu-related hospitalizations, and 5,000 fatalities due to the flu. Consequently, this rise in flu cases is fuelling the expansion of the antiviral market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2437&type=smp

Who Are the Major Industry Players Fueling Antivirals Market Expansion?
Major companies operating in the antivirals market include AbbVie Inc., Bristol-Myers-Squibb Co., Chemical Industrial & Pharmaceutical Laboratories Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Ltd., Merck & Co. Inc., Dr. Reddy's Laboratories Ltd., AstraZeneca plc, Aurobindo Pharma Ltd., Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi-Synthélabo Ltd., Regeneron Pharmaceuticals Inc., Inovio Pharmaceuticals Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Argos Distributors Limited, AVI Biopharma International Ltd., Moderna Inc., BioNTech SE, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Biogen Inc., Genentech USA Inc., Vertex Pharmaceuticals Inc.

Which Key Developments Are Influencing the Antivirals Market?
Leading companies in the antiviral market are prioritizing the creation of innovative therapies, such as oral antiviral treatment, to enhance patient convenience, increase accessibility, lower healthcare expenses, and offer more practical and efficient solutions for viral infections management. Oral antiviral treatments, which are medicines ingested orally to counter viral infections, operate by restricting the multiplication or spread of viruses in the body, reducing infection severity and duration. For example, in May 2023, Pfizer, a US pharmaceutical company, announced the FDA's approval of Paxlovid, positioning it as the first oral antiviral remedy for adults with COVID-19. This endorsement is particularly vital as it introduces a novel treatment option for COVID-19 management, particularly as the pandemic shifts towards an endemic phase. Paxlovid is specifically intended for adults with mild to moderate COVID-19 at high risk of developing severe disease, hospitalization, or death.

How Is the Segmentation of the Antivirals Market Defined?
The antivirals market covered in this report is segmented -

1) By Type: Branded, Generic
2) By Drug Class: DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other Drug classes
3) By Application: HIV, Hepatitis, Herpes, Influenza, Other Applications

Subsegments:
1) By Branded: Antivirals For HIV Or AIDS, Antivirals For Hepatitis, Antivirals For Influenza, Antivirals For Herpes Simplex Virus (HSV)
2) By Generic: Generic HIV Or AIDS Antivirals, Generic Hepatitis Antivirals, Generic Influenza Antivirals, Generic Herpes Simplex Virus (HSV) Antivirals

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

What Is the Leading Region in the Antivirals Market?
North America was the largest region in the anti-viral drug therapy market in 2023. The Middle East is expected to be the fastest-growing region in the antivirals market during the forecast period. The regions covered in the antivirals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Is Covered In The Antivirals Global Market Report?

- Market Size Analysis: Analyze the Antivirals Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Antivirals Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Antivirals Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Antivirals Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2437

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.